Comparison of the effect of dietary approaches to stop hypertension (DASH) diet to improve non-alcoholic fatty liver disease

Comparison of the effect of dietary approaches to stop hypertension (DASH) diet with regular hypocaloric diet on cardiometabolic parameters, oxidative stress and inflammatory markers, hepatic enzymes, and fatty liver severity in patients with non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121029011307N2

Enrollment

120

Registered

2020-03-03

Start date

2019-06-22

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group 1: Receiving dietary approaches to stop hypertension diet(DASH ). In this group, the required energy of each person will be determined based on Harris Benedict formu

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having a non alcoholic fatty liver disease (NAFLD) to diagnose a doctor (using Ultra Ultrasound) willing to participate in the study

Exclusion criteria

Exclusion criteria: Patients with cardiovascular disease, liver disease (cirrhosis, alcoholic liver disease, viral hepatitis, autoimmune hepatitis, primary bile cirrhosis, bile obstruction, liver damage induced by hereditary hemochromatosis drugs, sclerosis, and a-antitrypsin deficiency), other dire diseases Such as cancer, kidney failure and... Celiac Pregnancy, lactation Taking medications that cause fatty liver (methotrexate, tamoxifen, Oalprowat, etc.) Taking blood lipid-lowering drugs Malnutrition Having certain diets like vegetarian and raw veganism Alcohol consumption

Design outcomes

Primary

Measure	Time frame
Fatty liver severity. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Using Ultrasound.	—

Secondary

Measure	Time frame
Isoprostane 8. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;Interleukin 6. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;C-Reactive Protein. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;Aspartate aminotransferase. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Calorimetry method.	—

Measure

Time frame

Isoprostane 8. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;Interleukin 6. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;C-Reactive Protein. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;Aspartate aminotransferase. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Calorimetry method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Hatami Zargaran

Shiraz University of Medical Sciences

z_hatami_65@yahoo.com+98 71 3632 1066

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026